Premium
A new frontier in therapy personalisation based on in vitro studies to preserve fertility potential of men
Author(s) -
Zampieri Nicola,
Camoglio Francesco S.,
Dando Ilaria
Publication year - 2022
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.14244
Subject(s) - infertility , fertility , human chorionic gonadotropin , male infertility , human reproduction , medicine , male fertility , gynecology , bioinformatics , biology , pregnancy , hormone , genetics , population , environmental health , anatomy
At present, there is still a lack of attention to male infertility and fertility impairment. Indeed, the pathologies affecting the reproductive area in man are derived from anatomical or functional alterations of neuroendocrine system; thus, the study of these dysfunctions is necessary for a correct aetiopathogenetic and therapeutic framing of infertile patients. In this article, we underline the importance of the study of the molecular mechanisms regulated by the most common therapy used to treat infertile men, with the aim to highlight the necessity to avoid the administration of the wrong posology or, even more important, the wrong therapy to the patient. Accordingly, we present some pioneer data obtained on primary testicular cells cultured in vitro and treated with human chorionic gonadotropin (hCG). These data pave the way on the possibility to preliminarily test the effectiveness of the therapy in vitro, in order to identify the responsiveness of patient‐derived cells to the treatment and its effectiveness in each subject, in order to identify the correct dosage in a personalised way.